Adegoke Olubusi has stepped down as chief executive of Helium Health, marking his departure with a note thanking “Helium Humans, past and present” for a decade of work building the Nigerian health-tech company. No successor has yet been named, and it remains unclear whether Olubusi will retain a board or advisory role, as several of his counterparts elsewhere have done.

The exit extends a run of founder-CEO departures across Africa’s venture-backed technology sector that this publication has tracked over the past 18 months. The list now includes Tayo Oviosu at Paga, Katlego Maphai at Yoco, Sim Shagaya at uLesson, Andrew Garza at Lifestores Healthcare, Gregory Rockson at mPharma, Amir Allam at Elmenus, and Daniel Yu at Wasoko. Olubusi’s departure brings the total to at least eight. Helium Health, founded in 2016, is now ten years old, placing it squarely within the eight-to-fourteen-year tenure band at which the other founders stepped back.

But beneath that headline number, a sharper pattern is emerging: three of the eight exits — Lifestores Healthcare, mPharma, and now Helium Health — are health-tech companies, all unfolding within the same narrow window. That concentration makes the founder handover more than a general maturation story; it signals a sector-specific reckoning. Health-tech ventures in Africa burn through more capital and navigate longer, more complex sales cycles than their peers in fintech or logistics, while facing fragmented regulatory environments and sluggish procurement by insurers and public health systems. The result is a sharper tension between founder-led experimentation and the operational discipline that investors — many of whom backed these companies in the 2014–2016 defining early rounds — are now demanding as exit timelines compress. The post-pandemic funding surge that briefly lifted valuations has given way to a grindier commercial reality, and health-tech founders, often clinicians-turned-entrepreneurs who led through a global health crisis, are stepping back just as the sector enters its hardest scaling phase. Even more telling: British International Investment poured fresh capital into Ghana’s mPharma almost immediately after its CEO transition — a clear sign that institutional investors are rewarding the pivot to operational discipline

The broader pattern remains structural. Most of the companies involved raised their defining early rounds between 2014 and 2016, when African start-ups first drew serious institutional venture capital, and are now reaching the same inflection point together: early investors are seeking de-risked returns while founders confront the limits of their appetite for running large organisations. As Maphai put it on leaving Yoco, “the skills and energy needed to start and build a company are not always the same as those required to scale it to the next level” — a sentiment echoed, in substance, across several of the other announcements.

Helium Health’s own succession will be watched closely against three models already visible elsewhere. Some companies, including OfferZen and Twiga Foods, have hired external operators from outside the founding team, with boards citing the need for “operational grip” at scale. Others, including Paga, uLesson, and Lifestores, have promoted long-serving internal executives, trading proven scaling experience for continuity. Yoco took a third path, appointing Carsten Höltkemeyer, a German executive with no prior Africa experience, after a global search concluded that “the right scaling experience was not available locally” — an admission that pointed to a shortage of executives who combine regional knowledge with institutional scaling experience. In health-tech, where domain expertise is especially scarce, that talent gap will be tested severely: the pool of leaders who understand both Ghanaian drug supply chains and private-equity-style performance management is vanishingly small.

Whichever route Helium Health takes, it will also face the governance question that has followed the other transitions: whether an outgoing founder who retains influence, formally or informally, complicates the authority of an incoming chief executive brought in to professionalise operations. None of the companies that have completed this handover have addressed that tension publicly, and the arrangements remain largely untested over a multi-year horizon. That risk is amplified in a sector where the founder’s clinical credibility and regulatory relationships can be hard to separate from the company’s operational fabric.

Olubusi has not indicated his next move. Uniform board language — “operational discipline,” “the next phase” — signals investor pressure for exit-ready management rather than founder-led experimentation. Almost all departing CEOs have moved sideways rather than out, shifting to chairman or group roles. That creates a governance structure with no clear precedent, where the boundaries between strategic and operational authority will be tested by the commercial pressures facing incoming leaders.

The current wave is therefore less a conclusion than an early stress test of whether the continent’s first generation of founders built organisations that outlast them. For health-tech, where the exits are now piling up fastest, that test has already begun.